Testing whether a gene variant affects response to Humira in psoriasis
Tests Humira in adults with psoriasis, looking at an IL 12B gene variant.
Plain-language title generated from the registry record
Registry title: Evaluation of IL 12B Genetic Polymorphism (rs3213094)
Key facts
- Where
- Qina, EgyptSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07128472, who can take part
Where in Egypt
- Qina University hospital, South Valley University HospitalQina, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- South Valley University
- Trial code
- NCT07128472
- Record updated
- 19 August 2025
- Original description
Psoriasis is a skin disorder that is chronic proliferative and inflammatory in nature. Extensor surfaces, scalp, and lumbosacral area are covered in erythematous plaques with silvery scales. The disease can also impair the eyes and joints. It has no cure. Because of their low quality of life, many psoriasis patients experience depression. In addition to the cutaneous manifestations, it is associated with an increased risk of psoriatic arthritis, depression and cardiovascular disease.Read full original descriptionShow less
Evaluation of IL 12B Genetic Polymorphism (rs3213094) in Patient With Psoriasis and Psoriatic Arthritis in Response to Humira
Psoriasis is a skin disorder that is chronic proliferative and inflammatory in nature. Extensor surfaces, scalp, and lumbosacral area are covered in erythematous plaques with silvery scales. The disease can also impair the eyes and joints. It has no cure. Because of their low quality of life, many psoriasis patients experience depression. In addition to the cutaneous manifestations, it is associated with an increased risk of psoriatic arthritis, depression and cardiovascular disease.
Inclusion: Patients having psoriasis diagnosed clinically for at least 6 months and who have a severity grade of severe, defined as a Psoriasis Area and Severity Index (PASI) score greater than 10, and involvement of greater than 10% of the body surface area (BSA) with psoriatic arthritis.
Exclusion: Patients with other autoimmune or inflammatory conditions (e.g., rheumatoid arthritis, lupus); Patients with known genetic disorders affect immune system function; Patients with active infections, including tuberculosis or chronic viral infections (e.g., hepatitis B or C, HIV); Renal \&Vascular diseases; Pregnancy and lactation; Patients currently undergoing any treatment other than Humira; Patients were undergoing any treatment other than Humira in the last 6 months; Patients with contraindication to Humira.